NCT03997968 - A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors | Biotech Hunter

Enrollment

169

Participants

Timeline

Start Date

October 9, 2019

Primary Completion Date

November 30, 2024

Study Completion Date

December 20, 2024

Conditions

MalignancyNon-hodgkin LymphomaMultiple MyelomaBreast CancerOvarian CancerSoft Tissue SarcomaHead and Neck CancerDLBCLMantle Cell LymphomaFollicular LymphomaPancreatic CancerCLLSmall Cell Lung CancerSquamous Cell Carcinoma of Head and NeckTriple Negative Breast Cancer

Interventions

DRUG

CYT-0851

Part A and B: Daily oral doses of CYT-0851 for 28 day cycles

DRUG

CYT-0851 in combination with gemcitabine

Part D: Daily oral doses of CYT-0851 for 28 days in combination with gemcitabine

DRUG

CYT-0851 in combination with capecitabine

Part E: Daily oral doses of CYT-0851 for 21 days in combination with capecitabine

DRUG

CYT-0851 in combination with rituximab and bendamustine

Part C: Daily oral doses of CYT-0851 for 28 days in combination with rituximab and bendamustine

Trial Locations (16)

10016

NYU Langone Health, New York

19107

Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia

34232

Florida Cancer Specialists and Research Institute, Sarasota

37203

Sarah Cannon Research Institute at Tennessee Oncology, Nashville

48109

University of Michigan, Ann Arbor

53226

Medical College of Wisconsin, Milwaukee

55905

Mayo Clinic, Rochester

73104

Oklahoma University-Stephenson Cancer Center, Oklahoma City

77030

The University of Texas MD Anderson Cancer Center, Houston

80218

Sarah Cannon Research Institute at HealthONE, Denver

94158

University of California San Francisco, San Francisco

94305

Stanford Comprehensive Cancer Center, Stanford

98109

University of Washington Seattle Cancer Center, Seattle

02114

Massachusetts General Hospital, Boston

02115

Dana Farber Cancer Institute, Boston

07601

John Theurer Cancer Center at HUMC, Hackensack